Marciani Dante J
Galenica Pharmaceuticals, Inc., 2800 Milan Court, Suite 118, Birmingham, Alabama 35211, USA.
Drug Discov Today. 2003 Oct 15;8(20):934-43. doi: 10.1016/s1359-6446(03)02864-2.
Inactivated vaccines require adjuvants to stimulate an immune response. The choice of adjuvant or immune enhancer determines whether the immune response is effective, ineffective or damaging. Accordingly, there is a need for new adjuvants that stimulate the appropriate immunity, for example, T cell immunity for intracellular pathogens and cancer vaccines. In several adjuvants, the identification of chemical groups that interact with specific cell toll-like receptors (innate immunity) or receptors for co-stimulatory ligands (adaptive immunity), has enabled the establishment of structure-function relationships that are useful in the design of new adjuvants. Because of the crucial immunomodulating role of adjuvants, sub-unit vaccine development will remain dependent on new adjuvants.
灭活疫苗需要佐剂来刺激免疫反应。佐剂或免疫增强剂的选择决定了免疫反应是有效、无效还是具有损害性。因此,需要能够刺激适当免疫反应的新型佐剂,例如针对细胞内病原体和癌症疫苗的T细胞免疫。在几种佐剂中,对与特定细胞Toll样受体(固有免疫)或共刺激配体受体(适应性免疫)相互作用的化学基团的鉴定,使得建立在新型佐剂设计中有用的结构-功能关系成为可能。由于佐剂具有关键的免疫调节作用,亚单位疫苗的开发将仍然依赖于新型佐剂。